Drug Profile

LXPA 1788

Alternative Names: LXP-1788; LXPA-1788

Latest Information Update: 27 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LAUNXP Biomedical
Class Antineoplastics; Small molecules
Mechanism of Action Protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

31 Dec 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in Taiwan (IV) (NCT06883539)
31 Dec 2024 LAUNXP Biomedical has patent protection for LXPA 1788in Taiwan, the United States, Korea, China and Europe.(LAUNXP Biomedical pipeline; December 2024)
31 Dec 2024 LAUNXP Biomedical files an IND application with the US FDA and TFDA for phase-I trial in solid tumours (LAUNXP Biomedical pipeline; December 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com